Replimune jumps after FDA accepts resubmission for skin cancer drug
20/10/2025 15:09
Updates ** Shares of drug developer Replimune Group's REPL.O rise 99.1% to $8.96 ** Company says the U.S. FDA has accepted the resubmission of an application for its experimental therapy, RP1, in combination with Bristol Myers Squibb's BMY.N Opdivo for the treatment of advanced melanoma ** FDA is set to decide on the drug by April 10 ** The company received a complete response letter by the FDA in July this year citing insufficient data for substantial evidence of effectiveness ** Including session moves, stock down 22.8% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly